Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 2
2010 6
2011 3
2012 2
2013 3
2014 4
2015 6
2016 4
2017 4
2018 2
2019 4
2020 5
2021 8
2022 8
2023 8
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
The neurogliovascular unit in hepatic encephalopathy.
Claeys W, Van Hoecke L, Lefere S, Geerts A, Verhelst X, Van Vlierberghe H, Degroote H, Devisscher L, Vandenbroucke RE, Van Steenkiste C. Claeys W, et al. Among authors: van steenkiste c. JHEP Rep. 2021 Aug 11;3(5):100352. doi: 10.1016/j.jhepr.2021.100352. eCollection 2021 Oct. JHEP Rep. 2021. PMID: 34611619 Free PMC article. Review.
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Okhuysen PC, Ramesh MS, Louie T, Kiknadze N, Torre-Cisneros J, de Oliveira CM, Van Steenkiste C, Stychneuskaya A, Garey KW, Garcia-Diaz J, Li J, Duperchy E, Chang BY, Sukbuntherng J, Montoya JG, Styles L, Clow F, James D, Dubberke ER, Wilcox M. Okhuysen PC, et al. Among authors: van steenkiste c. Clin Infect Dis. 2024 Jun 14;78(6):1462-1472. doi: 10.1093/cid/ciad792. Clin Infect Dis. 2024. PMID: 38305378 Free PMC article. Clinical Trial.
An unexpected liver lesion?
De Somer T, D'Hondt M, Carels K, Monsaert E, Bouderez V, Vanderstraeten E, Alaerts H, Van Steenkiste C. De Somer T, et al. Among authors: van steenkiste c. Acta Gastroenterol Belg. 2021 Apr-Jun;84(2):385-386. doi: 10.51821/84.2.385. Acta Gastroenterol Belg. 2021. PMID: 34217196 Free article. No abstract available.
Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease.
Peleman C, Hellemans S, Veeckmans G, Arras W, Zheng H, Koeken I, Van San E, Hassannia B, Walravens M, Kayirangwa E, Beyene NT, Van Herck MA, De Vos WH, Pintelon I, van Nassauw L, Oosterlinck B, Smet A, Vits L, Dirinck E, Verrijken A, De Man J, Van Eyck A, Kwanten WJ, Vonghia L, Driessen A, Augustyns K, Toyokuni S, De Winter B, Van Steenkiste C, Francque S, Vanden Berghe T. Peleman C, et al. Among authors: van steenkiste c. Cell Death Differ. 2024 Sep;31(9):1113-1126. doi: 10.1038/s41418-024-01348-9. Epub 2024 Jul 26. Cell Death Differ. 2024. PMID: 39060422 Free PMC article.
Alteration of protein glycosylation in liver diseases.
Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H. Blomme B, et al. Among authors: van steenkiste c. J Hepatol. 2009 Mar;50(3):592-603. doi: 10.1016/j.jhep.2008.12.010. Epub 2008 Dec 27. J Hepatol. 2009. PMID: 19157620 Review.
67 results